BVF as of Sept. 30, 2012
Portfolio Holdings for BVF
BVF holds 32 positions in its portfolio as reported in the September 2012 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals | 14.8 | $73M | 7.1M | 10.25 | |
| Ligand Pharmaceuticals In (LGND) | 12.1 | $60M | 3.5M | 17.15 | |
| Chemocentryx | 11.8 | $58M | 5.0M | 11.63 | |
| Nektar Therapeutics | 9.2 | $45M | 4.2M | 10.68 | |
| Array BioPharma | 8.6 | $42M | 7.2M | 5.86 | |
| Ironwood Pharmaceuticals (IRWD) | 8.5 | $42M | 3.3M | 12.78 | |
| Qlt | 6.9 | $34M | 4.3M | 7.79 | |
| Targacept | 3.6 | $18M | 3.7M | 4.89 | |
| Endocyte | 3.3 | $16M | 1.6M | 9.97 | |
| ISIS Pharmaceuticals | 2.9 | $14M | 1.0M | 14.07 | |
| Pain Therapeutics | 2.7 | $13M | 2.6M | 5.05 | |
| Oncothyreon | 2.4 | $12M | 2.3M | 5.14 | |
| ArQule | 2.0 | $9.8M | 1.9M | 5.11 | |
| Exelixis (EXEL) | 2.0 | $9.6M | 2.0M | 4.82 | |
| A.P. Pharma (APPA) | 1.7 | $8.2M | 13M | 0.62 | |
| Cytokinetics | 1.6 | $7.6M | 9.2M | 0.83 | |
| Myrexis (MYRX) | 0.8 | $4.1M | 1.7M | 2.43 | |
| Palatin Technologies | 0.7 | $3.5M | 5.2M | 0.67 | |
| Hyperion Therapeutics | 0.7 | $3.4M | 322k | 10.63 | |
| DURECT Corporation | 0.6 | $3.0M | 2.1M | 1.44 | |
| Flamel Technologies | 0.5 | $2.6M | 643k | 4.09 | |
| AVANIR Pharmaceuticals | 0.5 | $2.5M | 782k | 3.20 | |
| Ym Biosciences | 0.4 | $2.0M | 1.1M | 1.84 | |
| Vanda Pharmaceuticals (VNDA) | 0.4 | $1.9M | 460k | 4.03 | |
| Genvec | 0.4 | $1.9M | 1.2M | 1.57 | |
| Sangamo Biosciences (SGMO) | 0.3 | $1.6M | 271k | 6.08 | |
| Capstone Therapeutics | 0.2 | $1.2M | 7.8M | 0.15 | |
| Transcept Pharmaceuticals | 0.2 | $797k | 150k | 5.31 | |
| Astex Pharmaceuticals | 0.1 | $570k | 186k | 3.07 | |
| Cadus Corporation | 0.1 | $380k | 269k | 1.41 | |
| NeurogesX | 0.1 | $251k | 1.2M | 0.21 | |
| AutoImmune (AIMM) | 0.0 | $0 | 3.6M | 0.00 |
